SY-1365

May 17, 2017

First Patient Dosed in Syros’ Phase 1 Trial for Ovarian, Other Solid Tumors

News

The first patient has been dosed in a Phase 1 trial assessing Syros Pharmaceuticals‘ investigative therapy SY-1365 in patients with advanced solid tumors, the company announced. The trial will particularly ... Read more

April 17, 2017April 17, 2017

Syros’ SY-1365 Displays Punch Against Ovarian Cancer, Studies Show

News

Syros Pharmaceuticals’ investigational compound SY-1365 showed potent anticancer activity in cell and animal models of ovarian cancer, giving the company momentum to move toward the Phase 1 trial it plans later ... Read more